

Reference:	FOI.15659.24
Subject:	Cancer treatments
Date of Request:	7 October 2024

Requested:

- 1) In the past 6 months, at your trust how many patients were treated with a combination of Dabrafenib + Trametinib for the following conditions:
 - a) Metastatic Melanoma
 - b) Adjuvant Melanoma
 - c) BRAF mutated Lung Cancer

- 2) In the past 6 months, at your trust how many patients were treated with a combination of Encorafenib (Braftovi) + Binimetnib (Mektovi) for the following conditions:
 - a) Metastatic Melanoma
 - b) Colorectal Cancer

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the number of patients for questions 1b, 1c and 2a, due to the low number of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. Therefore, the UHB is withholding these details under Section 40(2) of the Freedom of Information Act 2000 (FoIA).

This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

However, whilst operating in accordance with the Section 45 Freedom of Information Code of Practice, the UHB has a duty to provide advice and assistance, and can confirm that for questions 1a and 2b, no patients were treated with the stated cancer treatments.